BioWorld

July 29, 2013

Ligand Dusts Off Lasofoxifene, Signs 2 Deals for Pfizer Castoff

A few years after Ligand Pharmaceuticals Inc. regained the rights to its selective estrogen receptor modulator (SERM) lasofoxifene from Pfizer Inc., the company has dusted off the osteoporosis drug and found new parties interested in moving the molecule forward. Read More

Dormant Stem Cells Reveal Secrets About Skin Aging

It is a popular notion that on average we renew most of the cells in our body every seven years or so. Read More

Week in Review

Word on the Street

Week in Washington

Biotech Mergers And Acquisitions: March 1 - July 25, 2013#

Money Raised By Biotech In 2013 vs. 2012

Money Raised By Biotech: Jan. 1 - July 25, 2013

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for May 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 12, 2026

Alzheimer’s, beyond the brain

BioWorld

Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...

Hantavirus zoonotic spillover illustration

First cruise ship hantavirus genome points to zoonotic spillover

BioWorld

The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...

APAC monitors hantavirus as Singapore isolates 2 from cruise ship

BioWorld

Singapore’s Communicable Diseases Agency on May 7 said that it isolated two residents for hantavirus testing after the individuals disembarked from an Atlantic...